Relaxin Immunoglobulin Fusion Proteins for Targeted Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for various diseases and conditions such as acute heart failure, chronic heart failure, and fibrosis lack effective delivery mechanisms for relaxin peptides, limiting their therapeutic efficacy.
Innovation Solution
Development of relaxin immunoglobulin fusion proteins, specifically compositions comprising a relaxin therapeutic peptide connected to an antibody variable domain via a connecting peptide, to enhance the delivery and targeting of relaxin peptides to specific cells, tissues, or tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If relaxin peptides are administered alone, then they have therapeutic effects on cardiovascular diseases and fibrosis, but their delivery mechanism is insufficient and therapeutic efficacy is limited
Solution Approach 1:
The patent combines relaxin peptide with immunoglobulin (antibody) to create a fusion protein. The relaxin peptide sequence is fused to the N-terminus of the immunoglobulin heavy chain variable domain, creating a single molecule that integrates the therapeutic activity of relaxin with the delivery and targeting capabilities of the antibody structure.
Solution Approach 2:
The immunoglobulin structure serves as an intermediary carrier that enhances the delivery of the relaxin peptide to target cells and tissues. The antibody variable domain provides improved pharmacokinetic properties, stability, and cellular uptake, acting as a mediator between administration and therapeutic action.
2Adaptability or versatility
If relaxin peptides are delivered without targeting mechanisms, then they can reach general circulation, but they lack specific targeting to cells, tissues, or tumors
Solution Approach 1:
The patent merges the relaxin peptide sequence with the immunoglobulin variable domain to create a fusion protein that inherits the target recognition capabilities of the antibody structure while maintaining the therapeutic activity of relaxin.
Solution Approach 2:
The immunoglobulin variable domain provides multiple functions including enhanced stability, improved pharmacokinetics, cellular uptake enhancement, and potential targeting capabilities, making the fusion protein versatile for different therapeutic applications.
Data Source
AI summary
Disclosed herein are relaxin immunoglobulin fusion proteins useful for the treatment or prevention of a disease or condition in a subject.